Abstract

The Food and Drug Administration (FDA) has noted that animation within direct‐to‐consumer (DTC) pharmaceutical advertising may impact perceptions of risk or benefit, and that there have been few if any comprehensives studies of the impact animation may exert upon consumers. This article proposes that the use of animation in pharmaceutical advertising potentially disrupts the encoding process in the mind of the consumer, impacting perceptions of prescription drug benefits and risks. Using novel stimuli employing a rotoscoping technique, it is found that animation significantly reduces perceptions of perceived risk (but not benefits), and that this effect is driven by disruptions in encoding (Study 1). These findings are extended to examine deeper consumer inferences (Study 2). Implications for the pharmaceutical industry, consumer protection agencies, and consumers are considered.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.